OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 05, 2020
Research from data and analytics company GlobalData shows that CAR-T cell therapy innovations across APAC will make the global market for these therapies more competitive.
March 02, 2020
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.
The huge potential of biopharma is presenting an important epoch for outsourcing partners that can support the development and manufacture of biologics in an efficient way.
Can investing in early formulation studies drive a new therapy successfully across the commercialization finish line?
Formulating fixed-dose combination drugs proves more complex than simply adding one ingredient to another.
February 28, 2020
The partners will use ProBioGen’s DirectedLuck transposase technology to support development and large-scale manufacturing of ImmunOs’ biologics.
Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.
February 17, 2020
An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.
FDA’s Center for Biologics Evaluation and Research is planning on publishing nine specific guidance documents on gene therapies in 2020.
The agency is taking steps to monitor the supply chain and assist in the development of treatments.